Wedbush analyst Laura Chico raised the firm’s price target on PepGen to $22 from $17 and keeps an Outperform rating on the shares. PepGen’s Q4 report was largely in line with expectations, and Wedbush continues to hold a positive bias as execution continues and multiple clinical readouts are on track for 2024, the analyst tells investors in a research note.
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on PEPG:
- PepGen Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Developments
- PepGen to hold trials to assess safety and efficacy of repeated PGN-EDO51 doses
- PepGen Presents Clinical and Nonclinical Data at the 2023 Annual Muscular Dystrophy Association Clinical and Scientific Conference
- PepGen to Participate in the Stifel 2023 CNS Days Conference
- PepGen Announces Upcoming Data Presentations at the 2023 Annual Muscle Dystrophy Association Clinical and Scientific Conference